A Phase 2 Single Arm Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2019
Price : $35 *
At a glance
- Drugs Elotuzumab (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 30 Jul 2018 Status changed from active, no longer recruiting to completed.
- 15 May 2018 Planned End Date changed from 30 Mar 2018 to 15 Jun 2018.
- 27 Dec 2017 Planned End Date changed from 27 Nov 2017 to 30 Mar 2018.